The substantial increase in collaboration revenue and successful $135 million financing provide meaningful runway through 2029, reducing near-term dilution risk. Investors should monitor progress toward the CNTY-813 IND submission in Q4 2026 and initial clinical data in H2 2027 as key value inflection points. The reliance on collaboration revenue rather than product sales remains a structural concern for long-term sustainability.
Price Chart
Executive Summary
Century Therapeutics reported its 2025 financial results and provided business updates, highlighted by a $135 million private placement that extends its cash runway into Q1 2029. The company advanced its lead program, CNTY-813 for type 1 diabetes, into IND-enabling studies with an IND submission expected in Q4 2026 and initial clinical data anticipated in H2 2027. Despite a significant net loss reduction, the company remains pre-revenue with no product sales, relying on collaboration revenue and financing to fund operations.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $117.1 million as of December 31, 2025, down from $220.1 million in 2024
- Collaboration revenue increased to $109.2 million in 2025 from $6.6 million in 2024, driven by the Bristol-Myers Squibb agreement
- Net loss narrowed significantly to $9.6 million in 2025 from $126.6 million in 2024
- Completed $135 million private placement in January 2026, extending cash runway into Q1 2029
- CNTY-813 (beta islet cell therapy for type 1 diabetes) in IND-enabling studies with IND submission expected in Q4 2026
- CNTY-308 (CAR-iT cell therapy) on track to enter clinic in 2026
Financial Impact
Collaboration revenue increased by $102.6 million year-over-year to $109.2 million; $135 million financing extends cash runway significantly
Risk Factors
- High dependence on collaboration revenue from a single partner (Bristol-Myers Squibb)
- No product revenue generation as all programs remain in preclinical or early clinical stages
- Biotech pipeline risk with key programs still years away from potential approval
- Future financing needs beyond 2029 could lead to shareholder dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-026761 |
| Document: tm268574d1_ex99-2.htm | 0001104659-26-026761 |
| Document: tm268574d1_8k.htm | 0001104659-26-026761 |
| Document: 0001104659-26-026761-index-headers.html | 0001104659-26-026761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.46 (−4.58%) |
Oct 2, 2026 24d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.46 (−4.58%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.46 (−22.75%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.46 (−24.74%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.46 (−25.51%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.46 (+25.51%) |
Jun 16, 2026 18w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.46 (−35.11%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.46 (−33.03%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.46 (−31.13%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.46 (−31.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers